[HTML][HTML] Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine
Y Nomura, M Sawahata, Y Nakamura, M Kurihara… - Vaccines, 2021 - mdpi.com
Objective: We aimed to determine antibody (Ab) titres 3 months after the second dose of the
BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables …
BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables …
Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia
…, S Ikushima, T Ando, M Oritsu, M Sawahata… - …, 2012 - Wiley Online Library
Takemura T, Akashi T, Kamiya H, Ikushima S, Ando T, Oritsu M, Sawahata M & Ogura T (2012)
Histopathology Pathological differentiation of chronic hypersensitivity pneumonitis from …
Histopathology Pathological differentiation of chronic hypersensitivity pneumonitis from …
[HTML][HTML] Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan
M Sawahata, Y Sugiyama, Y Nakamura… - Respiratory …, 2015 - Elsevier
Background National surveys conducted in Japan between 1960 and 2004 suggest a gradually
increasing incidence of sarcoidosis in women >50 years old with increased involvement …
increasing incidence of sarcoidosis in women >50 years old with increased involvement …
[HTML][HTML] Attenuation of antibody titers from 3 to 6 months after the second dose of the BNT162b2 vaccine depends on sex, with age and smoking risk factors for lower …
Y Nomura, M Sawahata, Y Nakamura, R Koike… - Vaccines, 2021 - mdpi.com
Objective: We aimed to determine antibody titers at six months and their percentage change
from three to six months after the second dose of the BNT162b2 coronavirus disease 2019 (…
from three to six months after the second dose of the BNT162b2 coronavirus disease 2019 (…
[HTML][HTML] The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study
Objective To study how demographic differences impact disease manifestation of sarcoidosis
using the WASOG tool in a large multicentric study. Methods Clinical data regarding 1445 …
using the WASOG tool in a large multicentric study. Methods Clinical data regarding 1445 …
[PDF][PDF] An epidemiological perspective of the pathology and etiology of sarcoidosis
M Sawahata, Y Sugiyama - Sarcoidosis Vasc Diffuse Lung Dis, 2016 - researchgate.net
To update current knowledge on the pathology and etiology of sarcoidosis, here we review
previous epidemiological research and discuss age-related differences and historical …
previous epidemiological research and discuss age-related differences and historical …
[HTML][HTML] Computed tomography images of fibrotic pulmonary sarcoidosis leading to chronic respiratory failure
M Sawahata, T Johkoh, T Kawanobe, C Kono… - Journal of Clinical …, 2020 - mdpi.com
Background: There is currently no consensus on the morphology of severe fibrotic pulmonary
sarcoidosis, and we examined computed tomography (CT) findings and progression. …
sarcoidosis, and we examined computed tomography (CT) findings and progression. …
[HTML][HTML] Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination
R Koike, M Sawahata, Y Nakamura, Y Nomura… - Vaccines, 2022 - mdpi.com
Objective: We aimed to determine the relationship between vaccine-related adverse effects
and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 …
and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 …
Pulmonary mycobacteriosis caused by Mycobacterium peregrinum in a young, healthy man
M Sawahata, E Hagiwara, T Ogura… - Nihon Kokyuki Gakkai …, 2010 - europepmc.org
A 24-year-old male never-smoker with no contributory medical history was referred to our
division because of chronic productive cough and fever. His chest CT showed pulmonary …
division because of chronic productive cough and fever. His chest CT showed pulmonary …
[HTML][HTML] Imaging findings of fibrosis in pulmonary sarcoidosis
M Sawahata, T Yamaguchi - Sarcoidosis, Vasculitis, and Diffuse …, 2022 - ncbi.nlm.nih.gov
Background: In pulmonary sarcoidosis, respiratory tract lesions almost always appear, and
residual lung shadows require treatment in about 20% of cases. Pulmonary fibrosis is among …
residual lung shadows require treatment in about 20% of cases. Pulmonary fibrosis is among …